Summary by Futu AI
Avenue Therapeutics, a pharmaceutical company, has been actively engaging in various license agreements to bolster its product pipeline. The company has secured exclusive rights to IV tramadol for the U.S. market and has made significant payments to Revogenex and Polpharma related to this agreement, including milestone payments upon FDA approval and royalties on net sales. Additionally, Avenue has entered into license agreements with AstraZeneca and Cincinnati Children's Hospital Medical Center for compounds and intellectual property rights related to neurological disorders, with upfront fees and potential milestone and royalty payments. A recent agreement with AnnJi Pharmaceutical Co. Ltd. for AJ201 has led to upfront payments and obligations for future milestone payments and royalties based on net sales. Avenue's financial...Show More